- Therapeutic candidate GNbAC1 is first to target potential primary cause of MS
- Over 130 of 260 patients enrolled
- Clinical trial design presented during ECTRIMS Congress
- Primary data read-out confirmed in 4Q2017
Geneva, Switzerland, 14 September 2016 –GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), today announced that enrollment has reached the halfway mark, ahead of schedule, in the CHANGE-MS Phase 2b study of GNbAC1 in patients with relapsing-remitting multiple sclerosis (RRMS). GeNeuro provided the update at the 32nd ECTRIMS Congress, the world’s largest international conference devoted to basic and clinical research on MS, being held in London, UK (14-17 September).
Further information at :